Convergence of EGFR glioblastoma mutations: evolution and allostery rationalizing targeted therapy

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Epidermal Growth Factor Receptor (EGFR) mutations are common in glioblastomas.
• These mutations exhibit significant heterogeneity and organ-site asymmetry.
• Understanding the structural basis of EGFR heterogeneity is crucial for effective cancer therapy.

Purpose of the Study:

• To investigate the structural consequences of diverse extracellular EGFR mutations.
• To identify common structural intermediates despite mutational heterogeneity.
• To explore novel therapeutic strategies targeting these common conformations.

Main Methods:

• Utilized structural biology techniques to analyze EGFR conformations.
• Employed biochemical assays to assess protein function and interactions.
• Investigated synergistic targeting approaches using antibody and kinase inhibitors.

Main Results:

• Structurally diverse extracellular EGFR mutations converge to a similar intermediate conformation.
• This intermediate conformation is amenable to simultaneous extracellular and intracellular targeting.
• Demonstrated synergistic efficacy of antibody mAb806 and type-II kinase inhibitors.

Conclusions:

• EGFR mutation heterogeneity conceals an underlying structural convergence.
• Allostery-based co-targeting of this common intermediate conformation is a viable therapeutic strategy.
• Findings pave the way for developing more effective glioblastoma treatments.